CompletedPhase 1NCT02276963
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Studying Neuromyelitis optica spectrum disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Michael Levy, MD, PhDJohns Hopkins University
- Intervention
- Ublituximab(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2016 – 2019
Study locations (1)
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02276963 on ClinicalTrials.govOther trials for Neuromyelitis optica spectrum disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07377305Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)Tang-Du Hospital
- RECRUITINGNCT05891379Inebilizumab in Acute Neuromyelitis Optica Spectrum DisordersXuanwu Hospital, Beijing
- RECRUITINGNCT05004493Biorepository and Registry for Plasma Exchange PatientsCharles M Knudson
- RECRUITINGNCT04106830Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)Beijing Tiantan Hospital
- ACTIVE NOT RECRUITINGNCT01623076The Longitudinal CONQUER Study of Rare Neuroimmunologic DisordersUniversity of Texas Southwestern Medical Center